期刊文献+

注射用比阿培南治疗呼吸系统、泌尿系统细菌感染的随机对照多中心临床研究 被引量:10

Biapenem in treatment of respiratory and urinary bacterial infections:a multicenter,randomized,controlled clinical trial
原文传递
导出
摘要 目的评价注射用比阿培南治疗呼吸系统和泌尿系统细菌感染的疗效和安全性。方法采用多中心、随机、盲法、阳性药物平行对照试验方法,共入选288例呼吸系统和泌尿系统感染患者,随机分别接受比阿培南(试验组,144例)或美罗培南(对照组,144例)的治疗,统计两组的临床治愈率、细菌学疗效和不良反应发生率并进行比较。结果试验组和对照组临床治愈率分别为95.10%(136/143)和92.25%(131/142),呼吸系统感染治愈率分别为93.06%(67/72)和94.29%(66/70),泌尿系统感染治愈率分别为97.18%(69/71)和90.28%(65/72);试验组和对照组细菌清除率分别为88.00%(66/75)和92.65%(63/68),呼吸系统感染细菌清除率分别为83.33%(30/36)和90.62%(29/32),泌尿系统感染细菌清除率分别为92.31%(36/39)和94.44%(34/36);两组间临床治愈率、细菌学疗效比较差异无统计学意义(P>0.05);试验组不良反应发生率为2.08%(3/144),对照组为8.33%(12/144),两组间比较差异有统计学意义(P=0.030 6)。非劣效性检验结果显示,试验组的细菌清除率和综合疗效非劣于对照组成立。结论比阿培南治疗呼吸系统感染和泌尿系统感染的疗效与美罗培南相仿,安全性更好。 Objective To evaluate the efficacy and safety of biapenem in treatment of bacterial infections of the respiratory and urinary systems. Methods A total of 288 patients with infections of the respiratory and urinary system were included in this multicenter, blinded, randomized, and parallel controlled trial. The patients were randomly assigned to receive biapenem(experimental group, n=144) or meropenem (control group, n=144). Results The clinical curative rates of the experimental group and control group were 95.10%(136/143) and 92.25%(131/142), respectively, with those for respiratory system infection being 93.06%(67/72) and 94.29%(66/70) and those for urinary infection being 97.18%(69/71) and 90.28%(65/72), respectively. The bacterial eradication rates in the experimental group and control group were 88.00%(66/75) and 92.65%(63/68), respectively, with those for the respiratory infection being 83.33%(30/36) and 90.62%(29/32) and those for urinary infection being 92.31%(36/39) and 94.44%(34/36), respectively. There were no significant differences between the two groups regarding the clinical curative rates or bacterial eradication rates (P〉0.05).The side-effect rate was 2.08%(3/144) in the experimental group and 8.33%(12/144) in the control group, with significant differences found between the two groups (P=0.030 6). Conclusion Compared to meropenem, biapenem has similar efficacy in treatment of respiratory and urinary system infection, but with study
出处 《第二军医大学学报》 CAS CSCD 北大核心 2014年第4期388-393,共6页 Academic Journal of Second Military Medical University
关键词 比阿培南 美罗培南 细菌感染 呼吸系统 泌尿生殖系统 多中心研究 biapenem meropenem bacterial infections respiratory system urogenital system multicenter study
  • 相关文献

参考文献16

  • 1El-Gamal M I,Oh C H.Current status of carbapenemantibiotics[J].Curr Top Med Chem,2010,10:1882-1897.
  • 2Ackerman S H,Gatti D L.Biapenem inactivation by B2metallo(3-lactamases:energy landscape of the hydroly-sis reaction[J].PLoS One?2013,8:e55136.
  • 3Gomi K,Fujimura S,Fuse K,Takane H,Nakano Y,Kariya Y,et al.Antibacterial activity of carbapenems a-gainst clinical isolates of respiratory bacterial patho-gens in the northeastern region of Japan in 2007[J].JInfect Chemother,2011,17:200-206.
  • 4刘文静,王瑶,刘勇,赵旺盛,孙自镛,倪语星,孙宏莉,徐英春,谢秀丽,王辉,陈民钧.比阿培南等3种碳青霉烯类抗生素的体外抗菌活性[J].中国感染与化疗杂志,2010,10(6):468-471. 被引量:30
  • 5Ikawa K,Nakashima A,Morikawa N,Ikeda K,Muraka-mi YfOhge H,et al.Clinical pharmacokinetics of mero-penem and biapenem in bile and dosing considerationsfor biliary tract infections based on site-specific phar-macodynamic target attainment[J].Antimicrob AngensChemother,2011,55:5609-5615.
  • 6Karino F,Deguchi N,Kanda H,Ohe M,Kondo K,TadaM,et al.Evaluation of the efficacy and safety of biapenemagainst pneumonia in the elderly and a study on its phar-macokinetics[J].J Infect Chemother,2013?19:98-102.
  • 7郭智,陈惠仁,何学鹏,杨凯,陈鹏,刘兵,王丙然,刘晓东.比阿培南在血液科患者临床应用的有效性与安全性研究[J].中华医院感染学杂志,2011,21(10):2079-2081. 被引量:10
  • 8社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3117
  • 9抗菌药物临床试验技术指导原则(第二稿)[S].国家食品药品监督管理局药品审评中心,2007.
  • 10抗菌药物临床试验技术指导原则(第三稿)[S].国家食品药品监督管理局药品审评中心,2010.

二级参考文献52

  • 1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 2赵敏,赵国君,张勇.新碳青霉烯类抗生素比阿培南[J].中国临床药理学杂志,2005,21(5):390-392. 被引量:26
  • 3刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:792
  • 4刘成伟,涂植光,黄文祥,余登高,李崇智,郑行萍.比阿培南和亚胺培南对呼吸道和泌尿道致病菌的体外抗菌活性比较[J].中华检验医学杂志,2007,30(7):770-773. 被引量:14
  • 5Tsuchimochi N, Takuma T, Shimono N, et al. Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa [J]. J Infect Chemother, 2008,14(2) :99-104.
  • 6Drusano GL, Lode H, Edwards JR. Meropenem.- clinical re- sponse in relation to in vitro susceptibility[J7. Clin Microbiol Infect,2000,6 (4) :185-194.
  • 7Kiremitci A,Dinleyici EC,Erben N,et al. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey [J]. Expert Opin Pharmacother,2008,9(9) :1441-1449.
  • 8Endimiani A, Hujer KM ,Hujer AM, et al. Are we ready for novel detec-tion methods to treat respiratory pathogens in hospital-acquired pneumonia [J] ? Clin Infect Dis,2011 ;52(4) :S373-83.
  • 9ho M, Kaneko T, Goto H, et al. Clinical efficacy of carbapenems on hospi- tal-acquired pneumonia in accordance with the Japanese Respiratory Soci- ety Guidelines for management of HAP[ J). J Infect Chemother,2011 ;17 (3) :147-55.
  • 10El-Gamal MI, Oh CH. Current status of carbapenem antibiotics [ J]. Curr Top Med Chem,2010 ; 10( 18 ) : 1882-97.

共引文献3191

同被引文献120

引证文献10

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部